Through 2019, Amy L. Grogg, PharmD, held the position of Senior Vice President of Strategy and Commercialization at AmerisourceBergen. Dr. Grogg developed strategies to advance AmerisourceBergen's leadership in the pharmaceutical services industry and position AmerisourceBergen as the preferred commercialization partner for specialty pharmaceutical manufacturers. Additionally, Dr. Grogg held operational responsibility for Xcenda, part of AmerisourceBergen, which provides strategic consulting services for life sciences manufacturers commercializing products in the United States, Germany, and key global markets.
Prior to her commercialization role, Dr. Grogg was President of AmerisourceBergen Consulting Services where she led the growth of a portfolio of companies that included Xcenda, as well as Innomar Strategies, Canada's leading commercialization services firm for specialty pharmaceuticals; and Lash Group, the U.S. leader in patient support services. Before joining AmerisourceBergen, Dr. Grogg spent more than a decade in the pharmaceutical industry, primarily at Janssen Pharmaceuticals, (a Johnson & Johnson company), where she led teams that were responsible for all health economic, quality of life, and patient-reported outcomes research studies for all of the company's marketed products in the United States.
Dr. Grogg received her Doctor of Pharmacy from Mercer University and completed a two-year fellowship in pharmacoeconomics at Sandoz Pharmaceuticals Corporation and the University of South Carolina.